Tisotumab Vedotin: The First FDA-Approved Antibody-Drug Conjugate for Cervical Cancer | Bentham Science Publishers

2000

Volume 22, Issue 16

ISSN: 1871-5206
E-ISSN: 1875-5992

s Tisotumab Vedotin: The First FDA-Approved Antibody-Drug Conjugate for Cervical Cancer
By Surya K. De
Source: Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Volume 22, Issue 16, Oct 2022, p. 2808 - 2810
DOI: https://doi.org/10.2174/1871520622666220421095240
- Available online: 01 Oct 2022

Preview this article:

There is no abstract available.

© Bentham Science Publishers

Article metrics loading...

/content/journals/acamc/10.2174/1871520622666220421095240

2022-10-01

2024-12-26

From This Site

/content/journals/acamc/10.2174/1871520622666220421095240

dcterms_title,dcterms_subject,pub_keyword

-contentType:Contributor -contentType:Concept -contentType:Institution

10

5

Loading full text...

Full text loading...

/content/journals/acamc/10.2174/1871520622666220421095240

Article Type: Other

Most Cited Most Cited RSS feed

This is a required field

Please enter a valid email address

Approval was a Success

Invalid data

An Error Occurred

Approval was partially successful, following selected items could not be processed due to error

Please enter a valid_number test